Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Asterias Biotherapeutics Inc (AST)

Asterias Biotherapeutics Inc (AST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,319
  • Shares Outstanding, K 55,659
  • Annual Sales, $ 4,040 K
  • Annual Income, $ -28,370 K
  • 60-Month Beta 2.85
  • Price/Sales 70.66
  • Price/Cash Flow N/A
  • Price/Book 2.11
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.80 +18.12%
on 02/08/19
1.00 -5.50%
on 02/26/19
+0.10 (+12.37%)
since 02/07/19
3-Month
0.51 +85.29%
on 12/26/18
1.22 -22.54%
on 01/29/19
unch (-0.53%)
since 12/07/18
52-Week
0.51 +85.29%
on 12/26/18
2.05 -53.90%
on 03/13/18
-1.01 (-51.54%)
since 03/07/18

Most Recent Stories

More News
BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

--Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders

AST : 0.94 (unch)
BTX : 0.92 (-7.08%)
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company

BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc. (Asterias), whereby BioTime has acquired...

AST : 0.94 (unch)
BTX : 0.92 (-7.08%)
Biotech Companies Intensify Research Into New Therapies to Combat Cancer

Cancer ranks among one of the top causes of death globally and data show that the number is still expected to increase. The National Cancer Institute stated in 2012 there were 14.1 million new cases of...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
AST : 0.94 (unch)
GNCA : 2.23 (unch)
CYTR : 0.2700 (+1.89%)
NWBO : 0.2135 (-2.95%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Asterias Biotherapeutics, Inc. - AST

NEW YORK, NY / ACCESSWIRE / February 14, 2019 / , founder and managing partner at , a national securities firm headquartered at the Empire StateBuilding in New York City, is investigating the Board of...

AST : 0.94 (unch)
What Makes Asterias Biotherapeutics (AST) a New Buy Stock

Asterias Biotherapeutics (AST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AST : 0.94 (unch)
Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...

AST : 0.94 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade AST with:

Business Summary

Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem...

See More

Key Turning Points

2nd Resistance Point 0.98
1st Resistance Point 0.96
Last Price 0.94
1st Support Level 0.91
2nd Support Level 0.88

See More

52-Week High 2.05
Fibonacci 61.8% 1.46
Fibonacci 50% 1.28
Fibonacci 38.2% 1.10
Last Price 0.94
52-Week Low 0.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar